Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.
Executive Summary
Moreover, glucagon-Like Peptide-1 Receptor (GLP1R / GLP-1R) — the incretin hormone receptor that anchors the largest cardiometabolic commercial franchise in modern pharmaceutical history — has matured into a multi-mechanism, multi-modality therapeutic arena spanning Type 2 diabetes, obesity, MASH, cardiovascular outcomes, and emerging neurology and addiction indications. Notably, the field captures 771 active drug programs, 1,178 patent filings since January 2023, and 1,219 ongoing Phase 2 and Phase 3 trials.
Specifically, the GLP1R target landscape is anchored by Novo Nordisk’s Semaglutide (Ozempic, Wegovy, Rybelsus oral) and Eli Lilly’s Tirzepatide (GLP-1/GIP dual agonist Mounjaro, Zepbound) — collectively generating over $50B in annual revenue across diabetes and obesity. Moreover, the modality landscape spans 46 synthetic peptides (the dominant class with weekly and oral formulations), 32 small molecules (the emerging non-peptide oral GLP-1 class anchored by Lilly’s Orforglipron), 23 recombinant polypeptides, 16 Fc fusion proteins, 7 peptide hormones, 6 biological products, plus emerging dual / triple receptor agonists.
However, the strategic outlook is increasingly defined by oral GLP-1 receptor agonists, multi-receptor agonists (GLP-1/GIP duals, GLP-1/GIP/GCG triples), Chinese-developed follow-on entrants, and emerging cardiovascular outcomes plus MASH indications rather than incremental injectable peptide chemistry. As a result, Lilly’s Orforglipron (April 2026 FDA approval, first oral non-peptide GLP-1), Lilly’s Retatrutide (Phase 3 GLP-1/GIP/GCG triple), Novo Nordisk’s CagriSema (semaglutide + cagrilintide amylin), Innovent’s Mazdutide (GLP-1/GCG dual), Hengrui’s HRS9531 (GLP-1/GIP partnered with Kailera), Sciwind’s Ecnoglutide, and Roche’s CT-388 / CT-996 (Carmot acquisition) represent the active growth vectors.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.
Arena Overview
Pipeline by Modality
Across the 150 unique GLP1R-targeting programs sampled, synthetic peptides dominate with 46 entries reflecting the established weekly and oral peptide GLP-1 receptor agonist class, followed by 32 small molecules (the emerging oral non-peptide GLP-1 class led by Orforglipron), 23 recombinant polypeptides, 16 Fc fusion proteins, 7 peptide hormones, 6 biological products, 5 chemical drugs, 4 fusion proteins, 3 peptides, and emerging modalities. Notably, the rapid expansion of oral non-peptide small molecule GLP-1 agonists (32 programs) reflects the pharmaceutical industry’s pivot toward primary-care-friendly oral formulations that overcome injectable manufacturing capacity constraints.
Patent Filing Activity
However, patent activity since 2023 reflects intense innovation across GLP1R chemistry. Specifically, Shenzhen Salubris Pharma leads with 3 filings, followed by Nxera Pharma UK at 2 filings, plus multiple individual academic and corporate filers (Indian academic researchers and industry filers). Importantly, the dispersed patent landscape — with no single dominant assignee — reflects the broad chemistry diversity across peptide, small molecule, fusion protein, and emerging modalities. Moreover, big pharma incumbents (Lilly, Novo Nordisk, Pfizer, Roche/Carmot) maintain large patent portfolios that are diluted across the 1,178 total filings rather than appearing in concentrated top-assignee positions.
Player Summary Table
| Player | Region | Tier | Lead Asset | Key Evidence |
|---|---|---|---|---|
| Novo Nordisk | Denmark | Tier 1 — Leader | Semaglutide (Ozempic, Wegovy, Rybelsus) + CagriSema | Multi-billion GLP-1 + amylin franchise |
| Eli Lilly | US | Tier 1 — Leader | Tirzepatide + Orforglipron + Retatrutide | GLP-1/GIP + oral + triple agonist |
| Sanofi | France | Tier 1 — Leader | Lixisenatide (Adlyxin) + Soliqua | Insulin + GLP-1 combination franchise |
| AstraZeneca / BMS legacy | UK / US | Tier 2 — Active | Exenatide (Byetta, Bydureon) | Original GLP-1 RA legacy |
| Pfizer | US | Tier 2 — Active | Danuglipron + emerging oral GLP-1 | Phase 2 oral GLP-1 small molecule |
| Innovent Biologics | China | Tier 2 — Active | Mazdutide (GLP-1/GCG) | NMPA approval June 2025 |
| Hengrui / Kailera Therapeutics | China / US | Tier 2 — Active | HRS9531 (GLP-1/GIP) | Hengrui ex-China license $100M+ |
| Sciwind Biosciences | China | Tier 2 — Active | Ecnoglutide (XW003) | NMPA approval January 2026 |
| Roche / Carmot Therapeutics | Switzerland/US | Tier 2 — Active | CT-388 + CT-996 (oral GLP-1) | Carmot acquisition $2.7B+ |
| Hangzhou Jiuyuan Gene Engineering | China | Tier 2 — Active | Beinaglutide | NMPA-approved Chinese GLP-1 |
| Hanmi Pharmaceutical | South Korea | Tier 2 — Active | Efpeglenatide + LAPSGLP-2 | Korean weekly GLP-1 |
| Vivani Medical | US | Tier 3 — Emerging | Exenatide (NPM-115 implant) | FDA approval 2023; subdermal implant |
| Shenzhen Salubris Pharma | China | Tier 3 — Emerging | GLP-1 chemistry platform | 3 patents 2023+ |
| Nxera Pharma UK | UK | Tier 3 — Emerging | GLP-1 platform | 2 patents 2023+ |
| Vertex Pharmaceuticals | US | Tier 3 — Emerging | Exploratory GLP-1 + cell therapy | VX-880 islet platform |
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
Route Differentiation Analysis
| Route | Tier 1 Leaders | Tier 2 Active | Tier 3 Emerging | Strategic Position |
|---|---|---|---|---|
| Weekly injectable GLP-1 RA peptide | Novo Nordisk (Semaglutide), Lilly (Dulaglutide) | Multiple Chinese + Korean entrants | Multiple biosimilars in development | Saturated — multi-blockbuster |
| Daily injectable GLP-1 RA | Novo Nordisk (Liraglutide), AZ legacy (Exenatide) | Multiple regional players | Generic-dominated | Saturated — generic phase |
| Oral peptide GLP-1 RA | Novo Nordisk (Rybelsus) | Multiple second-gen oral peptide | Multiple Chinese filers | Active — Rybelsus precedent |
| Oral non-peptide small molecule GLP-1 RA | Lilly (Orforglipron) | Pfizer (Danuglipron), Roche (CT-996) | Multiple Chinese + emerging biotech | Differentiated — fastest-growing |
| GLP-1 / GIP dual agonist | Lilly (Tirzepatide) | Hengrui (HRS9531), multiple Chinese | Multiple second-gen | Strong — Tirzepatide leader |
| GLP-1 / GCG dual agonist | — | Innovent (Mazdutide), multiple second-gen | Multiple discovery-stage | Active — Chinese-led |
| GLP-1 / GIP / GCG triple agonist | — | Lilly (Retatrutide) | Multiple second-gen | Differentiated — emerging triple |
| GLP-1 + amylin (CagriSema class) | Novo Nordisk (CagriSema) | Multiple second-gen amylin | Several preclinical | Differentiated — combination strategy |
| Insulin + GLP-1 fixed-dose combination | Novo Nordisk (Xultophy), Sanofi (Soliqua) | Multiple regional generics | Generic-dominated | Active — diabetes maintenance |
| Subdermal GLP-1 implant | Vivani (NPM-115) | Multiple discovery-stage | Several preclinical | Emerging — long-acting delivery |
Route Concentration Observations
- Notably, oral non-peptide small molecule GLP-1 receptor agonists have emerged as the most strategically active route in 2025-2026, with Lilly’s Orforglipron April 2026 FDA approval validating non-peptide oral GLP-1 chemistry as a credible primary-care alternative to injectables.
- Moreover, GLP-1/GIP dual agonists led by Tirzepatide and emerging Chinese follow-ons (Mazdutide, HRS9531, Ecnoglutide) have established the dual-mechanism approach as standard for next-generation diabetes and obesity management.
- However, Lilly’s Retatrutide GLP-1/GIP/GCG triple agonist Phase 3 readouts will determine whether triple-mechanism chemistry justifies premium positioning over dual agonists in obesity and weight loss applications.
- In addition, GLP-1 + amylin combinations (Novo Nordisk CagriSema) and GLP-1 + cell therapy (Vertex VX-880 islet) represent the highest-novelty emerging routes addressing T2D and T1D respectively beyond standard receptor agonist mechanisms.
Top Player Deep Dives
Novo Nordisk (Semaglutide + CagriSema + Liraglutide Legacy)
Primary route: In addition, multi-mechanism GLP-1 franchise spanning Semaglutide (Ozempic / Wegovy / Rybelsus), Liraglutide (Victoza / Saxenda), Icodec Insulin (weekly basal), and emerging CagriSema (semaglutide + cagrilintide amylin combination). Specifically, Novo Nordisk holds the largest single GLP-1 franchise globally with multi-billion annual revenue across diabetes and obesity.
Key pipeline: As a result, semaglutide approved across T2D, obesity, CV outcomes, MASH, and chronic kidney disease; Icodec/Semaglutide FDC approved 2025; CagriSema Phase 3 obesity readouts. Moreover, Novo Nordisk has emerging high-dose Wegovy and pediatric obesity expansion programs.
Differentiation: Specifically, largest manufacturing scale globally; broadest GLP-1 indication footprint including SELECT cardiovascular outcomes and FLOW renal outcomes data. Furthermore, CagriSema represents the next-generation combination strategy.
Recent BD: Meanwhile, catalent acquisition (2024) for manufacturing scaling; multiple regional distribution arrangements.
Trajectory: In contrast, cagriSema Phase 3 readouts will determine next-generation positioning; oral GLP-1 (Rybelsus) competition from Lilly Orforglipron compresses growth.
Key risk: Similarly, lilly Tirzepatide and Retatrutide competition; Orforglipron oral non-peptide commercial launch may compress Rybelsus uptake; manufacturing capacity remains the critical commercial bottleneck.
Eli Lilly (Tirzepatide + Orforglipron + Retatrutide)
Primary route: Furthermore, multi-mechanism cardiometabolic franchise spanning Tirzepatide (Mounjaro / Zepbound, GLP-1/GIP injectable), Orforglipron (oral non-peptide GLP-1, FDA approval April 2026), and Retatrutide (GLP-1/GIP/GCG triple agonist Phase 3). Specifically, Lilly holds the most diverse cardiometabolic franchise globally with leadership across injectable, oral, and triple-mechanism categories.
Key pipeline: Additionally, tirzepatide approved across T2D, obesity, OSA; Orforglipron approved as the first oral non-peptide GLP-1; Retatrutide Phase 3 SURMOUNT obesity + diabetes. Moreover, Lilly is advancing weekly insulin and amylin co-formulations.
Differentiation: Importantly, combination of injectable GLP-1/GIP, oral non-peptide GLP-1, and triple-agonist platform supports comprehensive cardiometabolic management. As a result, Lilly is positioned as the single most important diabetes / obesity pharma globally.
Recent BD: Overall, lilly continues to invest internally; selective in-licensing for adjacent mechanisms.
Trajectory: Indeed, orforglipron commercial uptake will define the oral GLP-1 segment; Retatrutide Phase 3 readouts will determine triple-mechanism franchise viability.
Key risk: Consequently, manufacturing capacity for Tirzepatide and Orforglipron remains the critical commercial bottleneck; GLP-1 class oversupply could compress pricing.
Pfizer + Roche / Carmot (Oral Small Molecule GLP-1)
Primary route: Therefore, oral non-peptide small molecule GLP-1 receptor agonists from Pfizer’s Danuglipron (Phase 2) and Roche’s CT-996 + CT-388 (post-Carmot acquisition $2.7B+). Specifically, both companies represent significant Western big pharma commitments to capture a share of the oral GLP-1 market that Lilly Orforglipron is establishing.
Key pipeline: In particular, danuglipron in Phase 2 obesity development; CT-996 (oral GLP-1) and CT-388 (subcutaneous GLP-1/GIP) advancing under Roche. Moreover, both companies have additional cardiometabolic chemistry programs in development.
Differentiation: Likewise, differentiated chemistry profiles versus Orforglipron support potential 2L-3L positioning or specific PK / dosing advantages. Furthermore, Roche’s broader oncology + diabetes commercial scale supports comprehensive cardiometabolic franchise.
Recent BD: Thus, roche acquired Carmot Therapeutics in 2024 for $2.7B+ specifically to enter oral GLP-1 market; Pfizer retains internal control of Danuglipron.
Trajectory: For example, phase 2/3 readouts in 2026-2028 will determine oral non-peptide GLP-1 commercial trajectory beyond Orforglipron.
Key risk: At the same time, direct competition with established Orforglipron + Rybelsus oral GLP-1 leaders; Pfizer Danuglipron has experienced clinical setbacks affecting development trajectory.
Innovent + Hengrui + Sciwind + Hangzhou Jiuyuan (Chinese GLP-1)
Primary route: By contrast, multiple Chinese GLP-1 ecosystem includes Innovent’s Mazdutide (GLP-1/GCG, NMPA June 2025), Hengrui’s HRS9531 (GLP-1/GIP, partnered with Kailera Therapeutics for ex-China rights), Sciwind’s Ecnoglutide (NMPA January 2026), Hangzhou Jiuyuan’s Beinaglutide (NMPA approval), and Shenzhen Salubris Pharma (3 patents 2023+). Specifically, Chinese players represent the broadest regional GLP-1 ecosystem outside the US/Denmark.
Key pipeline: Of course, multiple Chinese GLP-1, GLP-1/GCG, and GLP-1/GIP molecules in NMPA-approved or Phase 3 development. Moreover, Hengrui-Kailera HRS9531 ex-China license ($100M+ upfront) validates Chinese GLP-1 commercial credibility globally.
Differentiation: Finally, pricing-led positioning supports rapid Chinese commercial expansion; multi-mechanism breadth across GLP-1 + GLP-1/GCG + GLP-1/GIP reflects discovery ecosystem maturity.
Recent BD: Notably, hengrui-Kailera HRS9531 ex-China license; Innovent maintains internal control of Mazdutide.
Trajectory: Moreover, continued NMPA market expansion; ex-China commercial scaling through 2027.
Key risk: However, limited Western regulatory engagement for Chinese GLP-1 molecules outside Kailera-Hengrui partnership; Lilly and Novo Nordisk dominance limits ex-China commercial opportunities.
Sanofi + AstraZeneca (Insulin + GLP-1 Combinations)
Primary route: In addition, insulin + GLP-1 fixed-dose combinations spanning Sanofi’s Soliqua (insulin glargine + lixisenatide) and AstraZeneca/BMS’s legacy Exenatide (Byetta, Bydureon). Specifically, both companies represent legacy GLP-1 commercial positioning that has been substantially eroded by Semaglutide and Tirzepatide leadership.
Key pipeline: As a result, soliqua + Lixisenatide retain niche commercial use in diabetes maintenance; AstraZeneca / BMS retain legacy Exenatide rights with limited continued investment.
Differentiation: Specifically, insulin + GLP-1 fixed-dose combinations support diabetes maintenance positioning; limited differentiation versus Semaglutide-driven oral and injectable franchise leadership.
Recent BD: Meanwhile, limited recent BD on GLP-1 specifically; both companies have shifted strategic focus to other therapeutic areas.
Trajectory: In contrast, continued legacy commercial trajectory; biosimilar entry from late 2020s further compresses franchise value.
Key risk: Similarly, generic Exenatide and Lixisenatide entry; Semaglutide dominance compresses combination commercial pathway.
Vivani Medical + Long-Acting Delivery Innovators
Primary route: Furthermore, subdermal long-acting GLP-1 implant technology (Vivani Medical NPM-115 / Exenatide implant, FDA approval October 2023) plus emerging biocompatible polymer + nanoparticle long-acting delivery platforms. Specifically, Vivani represents the most clinically advanced long-acting delivery approach for GLP-1 receptor agonists.
Key pipeline: Additionally, NPM-115 (Exenatide subdermal implant) is approved; Vivani has additional GLP-1 long-acting implant programs in development. Moreover, multiple academic and biotech players are advancing alternative long-acting delivery formats.
Differentiation: Importantly, subdermal implant supports differentiated patient adherence versus weekly + daily injection regimens; suitable for patients with adherence challenges.
Recent BD: Overall, vivani retains internal control; multiple academic partnerships extend the platform.
Trajectory: Indeed, continued NPM-115 commercial expansion; emerging GLP-1 implant alternatives in development.
Key risk: Consequently, limited commercial uptake post-launch; weekly + oral GLP-1 alternatives compress implant commercial pathway.
BD Deals & Strategic Moves
Deal Timeline
| Date | Deal | Parties | Type | Significance |
|---|---|---|---|---|
| 2026-04 | Orforglipron FDA approval | Eli Lilly | Regulatory | First oral non-peptide GLP-1 |
| 2026-01 | Ecnoglutide NMPA approval | Sciwind Biosciences | Regulatory | Chinese GLP-1 entrant |
| 2025-06 | Mazdutide NMPA approval | Innovent Biologics | Regulatory | Chinese GLP-1/GCG agonist |
| 2024-Q4 | Roche / Carmot acquisition | Roche ← Carmot | M&A | $2.7B+ for oral GLP-1 platform |
| 2024-Q3 | Hengrui-Kailera HRS9531 ex-China license | Kailera + Hengrui | License | $100M+ upfront for GLP-1/GIP |
| 2024 | Novo Nordisk / Catalent acquisition | Novo Nordisk ← Catalent | M&A | Manufacturing scale-up |
| 2023-10 | Vivani NPM-115 FDA approval | Vivani Medical | Regulatory | Subdermal Exenatide implant |
| 2022-05 | Tirzepatide FDA approval | Eli Lilly | Regulatory | First GLP-1/GIP dual agonist |
| 2017-12 | Semaglutide FDA approval | Novo Nordisk | Regulatory | Defining weekly GLP-1 + obesity |
Strategic Pattern
Notably, the BD landscape has consolidated around oral non-peptide GLP-1 platforms (Roche-Carmot $2.7B+) and emerging Chinese GLP-1 ex-China licensing (Hengrui-Kailera $100M+ upfront). Furthermore, Lilly and Novo Nordisk’s organic R&D dominance limits external BD activity from those incumbents. However, Roche’s Carmot acquisition signals that even diabetes-adjacent pharma is investing in oral GLP-1 chemistry to compete in obesity and cardiometabolic markets.
Unmet Needs & White Spaces
Opportunity Matrix
| Unmet Need | Current Approaches | Gap | White Space |
|---|---|---|---|
| Tirzepatide + amylin combinations | Multiple Phase 1/2 (CagriSema separately) | Limited approved combinations | GLP-1/GIP + amylin co-formulations |
| Pediatric obesity | Wegovy approved 12+; limited under-12 | Most products restricted to adolescents | Under-12 trials and formulations |
| MASH / NASH | Semaglutide ESSENCE Phase 3 | Limited approved MASH therapy | Resmetirom + GLP-1 combination |
| Cardiovascular outcomes (high-risk) | SELECT Semaglutide; SURPASS-CVOT Tirzepatide | Limited approved combinations | GLP-1 + Lp(a) / SGLT2 / PCSK9 multi-mechanism |
| GLP-1 in addiction / neurology | Multiple academic exploratory | Limited approved options | Alcohol use disorder, Alzheimer’s, addiction trials |
Risks and Strategic Outlook for 2026 and Beyond
Key Risks
- Notably, GLP-1 manufacturing capacity remains the critical commercial bottleneck for Lilly and Novo Nordisk; emerging follow-ons may compress pricing as supply meets demand.
- Moreover, Semaglutide and Liraglutide LOE in late 2020s will compress the established GLP-1 franchise; biosimilar competition further accelerates pricing erosion.
- However, GLP-1 RA cardiovascular safety profile (gastrointestinal toxicity, pancreatitis signal, thyroid C-cell tumor signal) constrains broader prescribing in elderly and high-risk populations.
- In addition, payer pressure on multi-billion GLP-1 spending may force reimbursement restrictions favoring generic SGLT2/DPP-4/metformin combinations and biomarker-stratified prescribing.
Strategic Outlook
Overall, GLP1R has consolidated as the largest commercial cardiometabolic target in modern pharmaceutical history, anchored by Novo Nordisk Semaglutide and Lilly Tirzepatide plus emerging Orforglipron oral chemistry. Furthermore, the next 24 to 36 months will be defined by Orforglipron commercial uptake, Retatrutide Phase 3 readouts, weekly insulin franchise scaling, Roche oral GLP-1 (CT-996) clinical-stage validation, Chinese GLP-1 ex-China expansion via Kailera and others, and the maturation of GLP-1 + amylin and GLP-1 + cell therapy combinations. Meanwhile, GLP-1 in MASH, cardiovascular outcomes, neurology, and addiction represents the longer-term differentiation that could expand GLP-1’s commercial reach beyond diabetes and obesity by 2030.
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
